[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneuploidy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneuploidy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,87,112,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642613","the-advance-assay-development-and-validation-for-pre-natal-and-obstetric-conditions-study-is-the-largest-us-based-prospective-study-demonstrating-a-circulating-fetal-cell-cfc-based-approach-to-non-invasive-fetal-risk-assessment-100642613",false,"NCT07643896","The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment","ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions","ADVANCE","Inclusion Criteria:\n\n* pregnant individuals between 10 and 20 weeks of gestation\n* singleton gestation\n\nExclusion Criteria:\n\n\\- active cancer","FEMALE",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.",[24,25,26,27,28,29,30],"Pregnant Individuals","Aneuploidy","Down Syndrome (Trisomy 21)","22q11.2 Deletion Syndrome","Trisomy 13","Trisomy 18","Sex Chromosome Abnormalities",[32,33,34,35,36],"pregnant","aneuploidy","NIPT","NIPS","circulating fetal cell","RECRUITING","2026-06-10",{"date":40,"type":41},"2026-06-12","ACTUAL",{"date":43,"type":41},"2026-01-10",{"date":45,"type":20},"2028-06",{"name":47,"class":48},"BillionToOne Inc.","INDUSTRY",6,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100370937","pregnancy-and-developmental-outcomes-after-transfer-of-reportedly-aneuploid-or-mosaic-embryos-100370937","NCT04109846","Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos","Transfer of Aneuploid or Mosaic Embryos Following Preimplantation Genetic Testing","TAME","Inclusion Criteria:\n\n* Available aneuploid or mosaic embryos\n* No other acceptable embryos available\n* Willing to travel to Stanford for treatment\n* English language fluency\n\nExclusion Criteria:\n\n* Use of international donor eggs or sperm not tested according to FDA guidelines.\n* Living outside the United States\n* Embryos with Triploidy are not eligible for transfer in this protocol",true,"18 Years","55 Years",{"count":62,"type":20},300,"INTERVENTIONAL",[65],"NA","To determine how often embryos reported to be abnormal by preimplantation genetic testing result in liveborn infants. To evaluate whether the pregnancies that result from these embryos are higher risk for complications and whether the resulting babies have higher risk for health or developmental issues in the first five years after birth.",[25,68,69],"Mosaicism","Pregnancy Outcome",[71,72,73,74,75],"Preimplantation Genetic Testing for Aneuploidy","Preimplantation Genetic Screening","embryo transfer","mosaic","aneuploid","2026-04-21",{"date":78,"type":41},"2026-04-24",{"date":80,"type":41},"2019-04-11",{"date":82,"type":20},"2039-04-01",{"name":84,"class":85},"Stanford University","OTHER",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":95,"studyType":21,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":86},"100595752","non-euploid-embryo-transfer-neet-registry-100595752","NCT07036536","Non-Euploid Embryo Transfer (NEET) Registry","The NEET Registry: a Prospective, Observational Study for Outcomes of Non-euploid Embryo Transfers (NEET)","Inclusion Criteria:\n\n* Patient is planning a non-euploid embryo transfer (NEET) at a fertility clinic in The Prelude Network.\n* Patient has signed informed consent to participate in the registry.\n\nExclusion Criteria:\n\n* Not applicable",{"count":19,"type":20},"5 Years","The NEET Registry is a registry to track and study the outcomes of non-euploid embryo transfers (NEET) in The Prelude Network",[98,68,25],"Infertility",[100,101,75,102],"IVF","PGT-A","FET","2025-06-24",{"date":105,"type":41},"2025-06-25",{"date":107,"type":41},"2024-09-23",{"date":109,"type":20},"2030-12",{"name":111,"class":48},"Inception Fertility Research Institute, LLC",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":120,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":86},"100586433","danish-prognostic-research-on-embryonic-diagnostics-involving-chromosomal-testing-100586433","NCT06915311","Danish Prognostic Research on Embryonic Diagnostics Involving Chromosomal Testing.","Assessment if Predictive Values of Preimplantation Genetic Testing for Aneuploidy (PGT.A). A Prospective, Blinded, Prognostic Cohort Study With the Aim of Determining if Preimplantation Genetic Testing for Aneuploidy Can be Used to Predict Clinical Outcomes.","DanPREDICT","Inclusion Criteria:\n\n* Undergoing preimplantation genetic testing for monogenic disorders (PGT-M)\n\nExclusion Criteria:\n\n* None","ALL",{"count":122,"type":20},220,"The study aim is to evaluate whether testing embryos for chromosomal abnormalities (known as aneuploidy) can aid in embryo selection.\n\nIf so, transfer of embryos that will fail to implant, miscarry or lead to birth of affected children, can be reduces. This would reduce the risk of miscarriage and increase the chance of healthy live birth per embryo transfer, which in turn would reduce the time and economical, physical and psychological cost associated with fertility treatment.\n\nThe method of genetically testing embryos for aneuploidy is know as preimplantation genetic testing for aneuploidy (PGT-A). It entails testing a biopsy from preimplantation embryos generated from assisted reproductive technology (ART) from which DNA can be analyzed. Another potential source of embryonic DNA is the spent culture media, the media in which the embryo has grown since the egg was fertilized with the sperm. Previous research suggest that the media contains DNA shed from the embryo during development. Hence, this a potential non-invasive way of obtaining DNA for PGT-A. Both embryo biopsy and spent culture media will be assessed in the study.\n\nThe study will be conducted as a prospective, blinded, prognostic cohort study in a cohort receiving preimplantation genetic testing for monogenic disorders (PGT-M). Hence, the study does not include an intervention, as data on aneuploidy is collected but not used to guide embryo selections and embryos are biopsied as part of standard care (PGT-M). Once clinical outcomes from embryo transfers has been collected from the study, the aneuploidy data will be assessed. Blinded towards the actual clinical outcome, predictions on whether each embryo would result in live birth or not will be made based on the aneuploidy results. Following prediction, actual clinical outcomes are revealed allowing calculation of predictive values. Predictive values will be calculated for PGT-A on embryos biopsies and spent culture media.\n\nTwo predictive values will be assessed. The positive predictive value (PPV) and the negative predictive value (NPV).\n\nThe PPV states how often an embryo predicted to result in live birth upon transfer actually did so. Numerous factors affect the chance of live birth besides aneuploidy, so while the PPV will never reach 100%, it should increase compared to the PPV of standard care (without testing for aneuploidy.\n\nThe NPV states how often an embryo predicted not to result in live birth upon transfer actually also failed to do so. The NPV should be near 100 %, which would mean that all or almost all embryos that would have been deselected did not result in live birth. If the NPV is too low, it means that too many embryos capable of resulting in live birth are being discarded, disqualifying PGT-A for clinical use.\n\nWith the predictive values assessed a proper evaluation of whether PGT-A should be used clinically can be made.\n\nA number of pre- and postnatal samples will be collected in the study to further validate PGT-A results. These include chorionic villus sampling, amniocentesis, Fetal cells isolated from maternal blood, products of conception and a DNA sample from the newborn. All of these samples can be consented to individually and as such are not required for participation in the study. Chorionic villus sampling and amniocenteses are only acquired if performed as part of routine care.\n\nThe study is expected to include 540 transfers requiring the recruitment of approximately 220 patients. Recruitment is expected to take two years combined at the two centers in Denmark participating in the study.",[25],[126,127,128,129],"Prognostic Cohort Study","Non-selection Study","Predictive Values","Preimplantation Genetic Testing for Aneuploidy (PGT-A)","2025-04-23",{"date":132,"type":41},"2025-04-25",{"date":134,"type":41},"2025-04-22",{"date":136,"type":20},"2030-05-01",{"name":138,"class":85},"Christian Liebst Frisk Toft",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":120,"minAge":4,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":63,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":86},"100517894","microfluidic-chip-vs-density-gradient-centrifugation-on-the-euploidy-rate-of-pre-implantation-genetic-testing-100517894","NCT06023472","Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing","A Randomized Comparison of Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing","Inclusion Criteria:\n\n* Women aged \\\u003C43 years at the time of ovarian stimulation for IVF\n* Women undergoing PGT for monogenic diseases, structural rearrangement of chromosomes or aneuploidy\n* Sperm concentration of the raw semen with at least 0.15 million motile sperm per ml or 100 motile sperm per 50 low power field (200x) of observation\n\nExclusion Criteria:\n\n* Use of frozen semen for insemination\n* Use of donor oocytes and spermatozoa\n* Submucosal fibroid or hydrosalpinx shown on pelvic scanning and not surgically treated;\n* Women who had been recruited into this study before and\n* Women joining other randomized trials","43 Years",{"count":148,"type":20},318,[65],"Infertile women attending for PGT at the Centre of Assisted Reproduction and Embryology, Queen Mary Hospital and Kwong Wah Hospital will be recruited during ovarian stimulation for IVF. Subsequently, they will be randomly assigned on the day of oocyte retrieval by a laboratory staff into one of the following two groups in a 1:1 ratio : (1) the microfluidic chip group and (2) the density gradient centrifugation group for sperm preparation and subsequent use in fertilization. Other IVF procedures will be the same as the standard practice of the Centre. Both women and clinicians will be blinded from the group allocation i.e. a double blind study.",[98,152,153,25],"Genetic Disease","Chromosomal Rearrangement",[155,156,157,158],"microfluidic chip","density gradient centrifugation","euploidy rate","pre-implantation genetic testing","2024-12-03",{"date":161,"type":41},"2024-12-06",{"date":163,"type":41},"2024-11-01",{"date":165,"type":20},"2028-11-30",{"name":167,"class":85},"Professor Ernest Hung-Yu Ng"]